Drug intelligence / Profile preview

bivalent subtype C gp120 + MF59

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A vaccine component consisting of two subtype C recombinant monomeric envelope proteins (TV1.C and 1086.C gp120s) combined with the MF59 adjuvant, a protein dose-sparing squalene oil-in-water emulsion. This vaccine component is delivered as a 0.5 mL intramuscular injection, containing 100 μg of each recombinant protein. It was developed as part of HIV vaccine regimens being tested in clinical trials, particularly as a replacement for the bivalent A244 (CRF01_AE) and subtype B MN gp120 proteins used in the RV144 trial.

Other names: bivalent subtype C gp120/MF59

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on bivalent subtype C gp120 + MF59.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bivalent subtype C gp120 + MF59.

Explore the full profile